BidaskClub Lowers Merus (MRUS) to Sell

Merus (NASDAQ:MRUS) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other equities analysts also recently commented on MRUS. ValuEngine raised shares of Merus from a “strong sell” rating to a “sell” rating in a report on Monday, April 2nd. Wedbush reaffirmed an “outperform” rating and set a $32.00 price objective on shares of Merus in a report on Friday, January 12th. Finally, Royal Bank of Canada downgraded shares of Merus from an “outperform” rating to a “sector perform” rating and set a $28.00 price objective for the company. in a report on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $30.00.

How to Become a New Pot Stock Millionaire

NASDAQ:MRUS opened at $16.91 on Friday. The stock has a market cap of $353.89, a PE ratio of -7.23 and a beta of 0.08. Merus has a 52 week low of $13.23 and a 52 week high of $23.75.

An institutional investor recently raised its position in Merus stock. Deutsche Bank AG lifted its holdings in shares of Merus NV (NASDAQ:MRUS) by 146.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 9,400 shares of the biotechnology company’s stock after acquiring an additional 5,588 shares during the period. Deutsche Bank AG’s holdings in Merus were worth $182,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 30.81% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at

Merus Company Profile

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with's FREE daily email newsletter.

Leave a Reply